Strides Pharma Science Ltd. has joined hands with Bangladesh-based Incepta Pharmaceuticals to introduce Medogen SubQ — the world’s first World Health Organization (WHO)-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) — across Africa.
The three-month injectable contraceptive can be administered by healthcare professionals or self-injected after proper training, offering women a discreet, convenient, and reliable birth control option. The product aims to enhance access to modern contraception, especially in underserved regions of low- and middle-income countries.
Developed by Incepta with support from the Children’s Investment Fund Foundation (CIFF) and the Gates Foundation, Medogen SubQ marks a major step in breaking the single-source supply chain for DMPA-SC, allowing health systems to source the product at more affordable prices.
“By bringing the WHO-prequalified product to Africa, we aim to expand choice and access for women, enabling them to take greater control of their reproductive health,” said Aditya Kumar, Executive Director, Business Development at Strides.
The partnership strengthens Strides’ women’s health portfolio in Africa, which already includes brands like Vitafer and L-Gest. The company said the move aligns with its “in Africa for Africa” strategy and its focus on impactful global collaborations.